Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqCM - Nasdaq Real Time Price USD

Verastem, Inc. (VSTM)

Compare
5.16
-0.54
(-9.47%)
At close: April 4 at 4:00:01 PM EDT
5.14
-0.02
(-0.39%)
After hours: April 4 at 5:23:49 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for VSTM

Recent News: VSTM

View More
Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade

Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade
Zacks 8 days ago
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
Business Wire 10 days ago

Verastem: Q4 Earnings Snapshot
Associated Press Finance 15 days ago
Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
Business Wire 15 days ago
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
Business Wire last month
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference
Business Wire 2 months ago
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
Business Wire 2 months ago
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer
Business Wire 2 months ago
Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China
Business Wire 2 months ago
Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025
Business Wire 2 months ago
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire 2 months ago
View More

Related Tickers

CRDF Cardiff Oncology, Inc.
2.7500
-4.18%
 
ABEO Abeona Therapeutics Inc.
4.5200
-8.69%
 
REPL Replimune Group, Inc.
7.46
-5.45%
 
KPTI Karyopharm Therapeutics Inc.
3.8600
0.00%
 
IMUX Immunic, Inc.
0.9950
-5.24%
 
RGNX REGENXBIO Inc.
6.29
-5.70%
 
URGN UroGen Pharma Ltd.
10.25
-2.66%
 
KALV KalVista Pharmaceuticals, Inc.
10.71
-5.39%
 
TENX Tenax Therapeutics, Inc.
5.80
-3.33%
 
DAWN Day One Biopharmaceuticals, Inc.
7.22
-6.36%